IFN-α represents the cytokine exhibiting the longest record of use in clinical oncology and many data support the concept that the antitumor response observed in IFN-treated cancer patients is mediated by an activation of immune cells, including T lymphocytes [6] and DC [35]. Here, IFNA1 is linked to cancer.